Cancer has been one of the most common life‐threatening diseases for a long time.
Traditional cancer therapies such as surgery, chemotherapy (CT), and radiotherapy (RT) …

The liver is the commonest site of metastatic disease for patients with colorectal cancer, with
at least 25% developing colorectal liver metastases (CRLM) during the course of their …

Colorectal carcinoma (CRC) is the third most common cancer, and approximately 35%-55%
of patients with CRC will develop hepatic metastases during the course of their disease …

BACKGROUND: This study was undertaken to determine outcomes of stereotactic body
radiotherapy for colorectal liver metastases in a pooled patient cohort. METHODS: Patients …

Purpose The main cause of death of colorectal cancer patients is metastatic disease.
Approximately 20–25% of the patients present with metastases at time of diagnosis. The …

Thetermoligometastases, introducedin19951 anddetailedmore recently, 2 describes an
intermediate state of cancer spread between localized disease and widespread metastases …

Background Selected patients with unresectable colorectal liver metastases (CLM) may be
rendered resectable after systemic chemotherapy. We reviewed the evidence of downsizing …

Objective: The aim of the study was to evaluate outcomes after resection of colorectal liver
metastases (CRLM) and concurrent extrahepatic disease (EHD), and to define prognostic …

BACKGROUND The selection of patients for oligometastasis‐directed ablative therapy
remains a challenge. The authors report on clinical and molecular predictors of survival from …

Background The FIRE-3 trial investigated combination chemotherapy plus either cetuximab
or bevacizumab in patients with untreated metastatic colorectal cancer (mCRC) not …